Opus Point Partners Management as of Dec. 31, 2018
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 39 positions in its portfolio as reported in the December 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
iShares NASDAQ Biotechnology Index (IBB) | 44.6 | $20M | 210k | 96.43 | |
Direxion Shs Etf Tr sp biotch bl | 5.0 | $2.3M | 69k | 32.85 | |
Proqr Thrapeutics N V shs euro (PRQR) | 4.8 | $2.2M | 139k | 15.78 | |
Mettler-Toledo International (MTD) | 4.0 | $1.8M | 3.2k | 565.69 | |
Illumina (ILMN) | 3.2 | $1.5M | 4.9k | 299.92 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 3.2 | $1.4M | 8.7k | 165.74 | |
Ionis Pharmaceuticals (IONS) | 2.6 | $1.2M | 22k | 54.06 | |
Seattle Genetics | 2.4 | $1.1M | 19k | 56.67 | |
Qiagen Nv | 2.4 | $1.1M | 32k | 34.45 | |
Alnylam Pharmaceuticals (ALNY) | 2.3 | $1.0M | 14k | 72.89 | |
Alexion Pharmaceuticals | 2.2 | $1.0M | 11k | 97.36 | |
Regeneron Pharmaceuticals (REGN) | 2.1 | $940k | 2.5k | 373.61 | |
Loxo Oncology | 1.9 | $870k | 6.2k | 140.10 | |
BioMarin Pharmaceutical (BMRN) | 1.8 | $826k | 9.7k | 85.17 | |
Incyte Corporation (INCY) | 1.7 | $776k | 12k | 63.58 | |
Celgene Corporation | 1.4 | $640k | 10k | 64.11 | |
Pacira Pharmaceuticals (PCRX) | 1.1 | $484k | 11k | 43.02 | |
Nektar Therapeutics (NKTR) | 1.0 | $435k | 13k | 32.90 | |
Exelixis (EXEL) | 0.9 | $426k | 22k | 19.68 | |
Intercept Pharmaceuticals In | 0.8 | $356k | 3.5k | 100.74 | |
Amgen (AMGN) | 0.7 | $328k | 1.7k | 194.66 | |
Biogen Idec (BIIB) | 0.7 | $320k | 1.1k | 301.32 | |
Grifols S A Sponsored Adr R (GRFS) | 0.7 | $315k | 17k | 18.34 | |
Fibrogen (FGEN) | 0.7 | $310k | 6.7k | 46.33 | |
Iqvia Holdings (IQV) | 0.7 | $307k | 2.6k | 116.16 | |
Charles River Laboratories (CRL) | 0.7 | $302k | 2.7k | 113.32 | |
Gilead Sciences (GILD) | 0.6 | $289k | 4.6k | 62.58 | |
United Therapeutics Corporation (UTHR) | 0.6 | $290k | 2.7k | 108.86 | |
Bluebird Bio (BLUE) | 0.6 | $271k | 2.7k | 99.12 | |
Bio-techne Corporation (TECH) | 0.6 | $255k | 1.8k | 144.72 | |
ACADIA Pharmaceuticals (ACAD) | 0.5 | $241k | 15k | 16.18 | |
Agios Pharmaceuticals (AGIO) | 0.5 | $236k | 5.1k | 46.14 | |
Ultragenyx Pharmaceutical (RARE) | 0.5 | $232k | 5.3k | 43.45 | |
Alkermes (ALKS) | 0.5 | $224k | 7.6k | 29.45 | |
Neurocrine Biosciences (NBIX) | 0.5 | $213k | 3.0k | 71.33 | |
Checkpoint Therapeutics | 0.5 | $205k | 113k | 1.82 | |
Fortress Biotech | 0.4 | $201k | 234k | 0.86 | |
Intrexon | 0.4 | $177k | 27k | 6.53 | |
Recro Pharma | 0.2 | $81k | 11k | 7.13 |